Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: A randomized, multicentre, double-blind study

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 1, 2007, Pages 112-120

  File Jr , Thomas M ^a,b   Mandell, Lionel A ^c,g   Tillotson, Glenn ^d   Kostov, Kosta ^e   Georgiev, Ognian ^f  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d GENOME THERAPEUTICS CORPORATION   (United States)

^e MILITARY MEDICAL ACADEMY   (Bulgaria)

^f Alexandrovska University   (Bulgaria)

^g Replidyne Inc   (United States)

Author keywords

CAP; Fluoroquinolones; Phase III; Resistance; Short course therapy

Indexed keywords

GEMIFLOXACIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTRITIS; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERGLYCEMIA; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PARALLEL DESIGN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; UPPER ABDOMINAL PAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; NAPHTHYRIDINES; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 34447556820     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm119     Document Type: Article

References (35)

1. Niederman MS, McCombs JS, Unger AN et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37.
2. Lutfiyya MN, Henley E, Chang LF et al. Diagnosis and treatment of community-acquired pneumonia. Am Fam Physician 2006; 73: 442-50.
3. Musher DM, Alexandraki I, Graviss EA et al. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) 2000; 79: 210-21.
4. File TM. Community-acquired pneumonia. Lancet 2003; 362: 1991-2001.
5. Infectious Diseases Society of America and American Thoracic Society. Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-72.
6. Pass SE, Gearhart MM, Young EJ. Short-course antimicrobial therapy for the treatment of pneumonia. J Pharm Pract 2005; 18: 18-24.
7. File TM, Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 2004; 39 Suppl 3: 159-64.
8. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 2005; 118 Suppl 7A: 21-8.
9. Goff DA. Short-duration therapy for respiratory tract infections. Ann Pharmacother 2004; 38: 19-23.
10. Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: A randomised trial. JAMA 2001; 286: 49-56.
11. Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin Infect Dis 2003; 37: 752-60.
12. Mandell LA, File TM, Jr. Short-course treatment of community-acquired pneumonia. Clin Infect Dis 2003; 37: 761-3.
13. Powis J, McGeer A, Green K et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 2004; 48: 3305-11.
14. Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2005; 25: 717-40.
15. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004; 98: 708-20.
16. Begg C, Cho M, Eastwood S et al. Improving the quality of reporting of randomised controlled trials. The CONSORT statement. JAMA 1996; 276: 637-9.
17. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
18. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing M100-S8. NCCLS, Villanova, PA, USA, 1998.
19. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A5 NCCLS document M100-S10/M7. NCCLS, Wayne, IL, USA, 2000.
20. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tasts - Fifth Edition: Approved Standard M2-A5. NCCLS, Villanova, PA, USA, 1993.
21. US Food and Drug Administration. Guidance for Industry. http://www.fda.gov/cder/guidance/old043fn.pdf:// (14 January 2007, date last accessed).
22. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978; 62: 1037-40.
23. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
24. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
25. Akpunonu B, Michaelis J, Uy C et al. Postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin Infect Dis 2004; 38 Suppl 1: 5-15.
26. Church D, Haverstock D, Andriole VT. Moxifloxacin: A review of its safety profile based on worldwide clinical trials. Today's Ther Trends 2000; 18: 205-23.
27. Jinks MF, Kelly CA. The pattern and significance of abnormal liver function tests in community-acquired pneumonia. Eur J Intern Med 2004; 15: 436-40.
28. Iannini P, Mandell LA, Patou G et al. Cutaneous adverse events and gemifloxacin: Observations from the clinical trial program. J Chemother 2006; 18: 3-11.
29. File TM, Jr, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 993-1016.
30. Hoepelman IM, Mollers MJ, van Schie MH et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents 1997; 9: 141-6.
31. O'Doherty B, Muller O. Randomised, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17: 828-33.
32. el Moussaoui R, de Borgie CA, van den BP et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community-acquired pneumonia: Randomised, double blind study. BMJ 2006; 332: 1355.
33. Tellier G, Niederman MS, Nusrat R et al. Clinical and bacteriologic efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004; 54 515-23.
34. Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of β-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279 365-70.
35. Scheld WM. Maintaining fluoroquinolone class efficacy: Review of influencing factors. Emerg Infect Dis 2003; 9: 1-9.